Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Major Pharmas Tie Up with Generic Firms: Seminar
September 10, 2007
- REGULATORY NEWS IN BRIEF
September 10, 2007
- JGPRG to Designate Oct. as "Generic Drug Promotion Month"
September 10, 2007
- NBI to Go on Offensive in the Market for ARBs with 1,000 MRs
September 10, 2007
- GENERICS NEWS IN BRIEF
September 10, 2007
- SELF-MEDICATION NEWS IN BRIEF
September 3, 2007
- R&D NEWS IN BRIEF
September 3, 2007
- Daiichi Sankyo Ties Up with Forest Lab. for AZOR
September 3, 2007
- Japan Tissue Engineering's Autologous Epidermis Recommended for Approval
September 3, 2007
- Teijin to Codevelop Ipsen's ITM-077 with Chugai
September 3, 2007
- MEDICAL DEVICE NEWS IN BRIEF
September 3, 2007
- Peptisyntha to Expand Contract Peptide Manufacturing Business in Japan
September 3, 2007
- Drugs Account for 21.7% of Medial Expenditure
September 3, 2007
- DSP to Increase Its MRs' Scientific Knowledge
September 3, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2007
- Wholesalers' Operating Profit Ratio Exceeds 1% for the 1st Time in 8 Years
September 3, 2007
- Enuresis Causes Stress in Over 70% of Children and Parents
September 3, 2007
- Japanese Companies Are at Greater Risk of Takeover than US, European Companies: Mr Ota
September 3, 2007
- Daiichi Sankyo Healthcare to Launch Japan's First Drug to Improve Chloasma
September 3, 2007
- BUSINESS NEWS IN BRIEF
September 3, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…